Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Octenidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | HTT | P42858 | 6/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GALR3 | O60755 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.53 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octenidine SCHEMBL2594550 | 0.98 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL20764598 | 0.97 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| Pirtenidine SCHEMBL2108103 | 0.97 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL10570053 | 0.97 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL10569601 | 0.97 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL23393769 | 0.97 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL124821 | 0.97 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL16836483 | 0.95 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Hydrochloric Acid SCHEMBL10573221 | 0.95 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL20597431 | 0.95 | NPC1 (0.59) | NPC1RAB9AHTTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736644-A1 | BIOFILM REMOVER COMPOSITION | Kao Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736643-A1 | BIOFILM GERMICIDE COMPOSITION | Kao Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-3771337-B1 | ANTIMICROBIAL COMPOSITION | PROCTER & GAMBLE (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2025121754-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING JANUS KINASE INHIBITOR | 장병모 | 2025-06-12 | — | — | WO | disclosed |
| WO-2025110651-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES | 장병모 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025100865-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PSORIASIS AND ATOPIC DERMATITIS | 장병모 | 2025-05-15 | — | — | WO | disclosed |
| CN-119923247-A | Compositions with improved SPF and UVA photoprotection | 西姆莱斯股份公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025004478-A1 | BIOFILM GERMICIDE COMPOSITION | 花王株式会社 | 2025-01-02 | — | — | WO | disclosed |
| WO-2025004479-A1 | BIOFILM REMOVER COMPOSITION | 花王株式会社 | 2025-01-02 | — | — | WO | disclosed |
| EP-2113237-B1 | Dental materials with anti-plaque agents | HERAEUS KULZER GMBH (DE) | 2014-12-10 | — | — | EP | disclosed |
| WO-2014153238-A9 | COMPOSITIONS, METHODS AND DEVICES FOR PROMOTING WOUND HEALING AND REDUCING INFECTION | IASIS MOLECULAR SCIENCES (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014153238-A2 | COMPOSITIONS, METHODS AND DEVICES FOR PROMOTING WOUND HEALING AND REDUCING INFECTION | IASIS MOLECULAR SCIENCES (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2613758-A2 | MACROEMULSIONS WITH IMPROVED DEODORANT EFFICACY | Beiersdorf AG (DE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012031987-A2 | OCTENIDINE DIHYDROCHLORIDE AS CO-EMULSIFIER IN MICROEMULSIONS | BEIERSDORF AG (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012031984-A2 | MACROEMULSIONS WITH IMPROVED DEODORANT EFFICACY | BEIERSDORF AG (DE) | 2012-03-15 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090297458-A1 | Dental materials equipped with active anti-plaque substance(s) | HERAEUS KULZER GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| EP-2113237-A1 | Dental materials with anti-plaque agents | Heraeus Kulzer GmbH (DE) | 2009-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | NPC1 3898/4885RAB9A 4780/4885HTT 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.